| 119. A Humanized Antibody Targeting the CotH Invasins is Protective Against Murine Mucormycosis Y Gu, A Alqarihi, S Singh, T Gebremariam, S Alkhazraji, E Youssef, ... Open Forum Infectious Diseases 8 (Suppl 1), S71, 2021 | 2 | 2021 |
| 1248. Efficacy and safety of oral Ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI) BD Alexander, O Cornely, P Pappas, R Miller, JA Vazquez, ... Open Forum Infectious Diseases 7 (Supplement_1), S642-S642, 2020 | 4 | 2020 |
| 1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the … M Zhao, AJ Lepak, DR Andes Open Forum Infectious Diseases 5 (suppl_1), S424-S424, 2018 | | 2018 |
| 1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA … AJ Lepak, M Zhao, Q Liu, P Wang, Y Wang, JC Bader, PG Ambrose, ... Open Forum Infectious Diseases 5 (suppl_1), S426-S426, 2018 | 1 | 2018 |
| 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the … JM Pogue, RN Jones, JS Bradley, D Andes, SM Bhavnani, M Dudley, ... Open Forum Infectious Diseases 6 (Supplement_2), S559-S559, 2019 | 1 | 2019 |
| 1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates MA Pfaller, RK Flamm, PG Ambrose, D Andes, JS Bradley, SM Bhavnani, ... Open Forum Infectious Diseases 6 (Supplement_2), S580-S580, 2019 | | 2019 |
| 1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States RK Flamm, MA Pfaller, PG Ambrose, D Andes, JS Bradley, SM Bhavnani, ... Open Forum Infectious Diseases 6 (Suppl 2), S580, 2019 | | 2019 |
| 16 Antifungal Agents Pharmacokinetics and Pharmacodynamics of Amphotericin B D Andes in Theory and Clinical Practice, 315, 2007 | 2 | 2007 |
| 2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1st - 3rd Generation Cephalosporins against S. aureus and E. coli in the Mouse … A Lepak, SM Bhavnani, C Vincent, BD VanScoy, HS Sader, D Andes Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2169, 2023 | 1 | 2023 |
| 2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology … SM Bhavnani, NJ Onufrak, JP Hammel, DR Andes, JS Bradley, RK Flamm, ... Open Forum Infectious Diseases 5 (suppl_1), S71-S71, 2018 | 13 | 2018 |
| 346: CLINICAL OUTCOME ASSESSMENT OF THREE ANTI-METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AGENTS L Schulz, E Hendrick, D Andes Critical Care Medicine 40 (12), 1-328, 2012 | | 2012 |
| 406. Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients With Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT) EK McCreary, J Borlagdan, DR Andes, P Kinn, LT Schulz, AJ Lepak Open Forum Infectious Diseases 5 (Suppl 1), S156, 2018 | 1 | 2018 |
| 7 Authors: 8 Alexander J. Lepaka, Karen Marchilloa, Jamie vanHeckera, David R. Andesa 9 DR Andes | | 2013 |
| 992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI) JA Vazquez, O Cornely, P Koehler, R Rautemaa-Richardson, R Bazaz, ... Open Forum Infectious Diseases 8 (Supplement_1), S586-S587, 2021 | | 2021 |
| A Candida auris–specific adhesin, Scf1, governs surface association, colonization, and virulence DJ Santana, JAE Anku, G Zhao, R Zarnowski, CJ Johnson, H Hautau, ... Science 381 (6665), 1461-1467, 2023 | 26 | 2023 |
| A Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance HT Taff, JE Nett, R Zarnowski, KM Ross, H Sanchez, MT Cain, J Hamaker, ... Public Library of Science 8 (8), e1002848, 2012 | 325 | 2012 |
| A common vesicle proteome drives fungal biofilm development R Zarnowski, H Sanchez, A Jaromin, UJ Zarnowska, JE Nett, AP Mitchell, ... Proceedings of the National Academy of Sciences 119 (38), e2211424119, 2022 | 24 | 2022 |
| A dual‐responsive antibiotic‐loaded nanoparticle specifically binds pathogens and overcomes antimicrobial‐resistant infections M Ye, Y Zhao, Y Wang, M Zhao, N Yodsanit, R Xie, D Andes, S Gong Advanced Materials 33 (9), 2006772, 2021 | 105 | 2021 |
| A histone deacetylase complex mediates biofilm dispersal and drug resistance in Candida albicans CJ Nobile, EP Fox, N Hartooni, KF Mitchell, D Hnisz, DR Andes, K Kuchler, ... MBio 5 (3), 10.1128/mbio. 01201-14, 2014 | 84 | 2014 |
| A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against Candida albicans Biofilms R Zarnowski, A Jaromin, A Zagórska, EG Dominguez, K Sidoryk, ... International Journal of Molecular Sciences 22 (1), 108, 2020 | 5 | 2020 |
